Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. - Wikidata - wikimedia - TriplyDB

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

http://www.wikidata.org/entity/Q47607188

about

Life Impact and Treatment Preferences of Individuals with Asthma and Chronic Obstructive Pulmonary Disease: Results from Qualitative Interviews and Focus Groups.The Burden of Illness Related to Chronic Obstructive Pulmonary Disease Exacerbations in Québec, Canada Monitoring safety in a phase III real-world effectiveness trial: use of novel methodology in the Salford Lung Study Obesity paradox and mortality in adults with and without incident type 2 diabetes: a matched population-level cohort study.Raising Standards for the Evaluation of Future Psoriasis Therapeutics: A Critical Checklist.Could phase 3 medicine trials be tagged as pragmatic? A case study: The Salford COPD trial.Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators.Use of External Controls in Regulatory Decision-Making.Phenotyping Before Starting Treatment in COPD?The Salford Lung Study: a pioneering comparative effectiveness approach to COPD and asthma in clinical trials.The Range and Scientific Value of Randomized Trials.Salford Lung Study in chronic obstructive pulmonary disease (SLS COPD): follow-up interviews on patient-centred outcomes.Inhaled therapies in patients with moderate COPD in clinical practice: current thinking.Consumer segmentation and time interval between types of hospital admission: a clinical linkage database study.Update in Chronic Obstructive Pulmonary Disease 2016.At the Root: Defining and Halting Progression of Early Chronic Obstructive Pulmonary Disease.Sources of Safety Data and Statistical Strategies for Design and Analysis: Real World Insights.Low-dose Fluticasone Propionate in Combination With Salmeterol in Patients With Chronic Obstructive Pulmonary Disease.COPD in 2016: some answers, more questions.Automated recruitment and randomisation for an efficient randomised controlled trial in primary care.Betamethasone prevents human rhinovirus- and cigarette smoke- induced loss of respiratory epithelial barrier function.GOLD 2017 recommendations for COPD patients: toward a more personalized approach The TRANSFoRm project: Experience and lessons learned regarding functional and interoperability requirements to support primary care Study investigating the generalisability of a COPD trial based in primary care (Salford Lung Study) and the presence of a Hawthorne effect Real world evidence (RWE) - a disruptive innovation or the quiet evolution of medical evidence generation?Cost-consequence analysis of fluticasone furoate/vilanterol 92/22 mcg for the management of COPD in the Spanish NHS Evaluating the Impact and Benefits of Fluticasone Furoate/Vilanterol in Individuals with Asthma or COPD: A Mixed-Methods Analysis of Patient Experiences Valuing health-related quality of life: systematic variation in health perception Understanding low COPD exacerbation rates in Japan: a review and comparison with other countries

P2860

Q33844382-00416BD6-24BE-4472-A590-D0309ED8A363 Q33868106-4899B9BB-820E-4963-ACB3-C771A295DFD1 Q37696453-4E33B562-FA36-4511-BF69-B4F2B372D1ED Q37704275-EB1AA00C-11D6-4486-86BD-A862E6C6B3D8 Q38658837-C9E62654-9434-4198-A516-CED1F032F609 Q38689738-3517C772-417D-4CAB-962F-B7386EEBFF55 Q38751226-251F5F20-5E08-418B-9C96-0294D03CD6E4 Q38969906-651BB01D-1A19-41F6-BDF8-A767810D7132 Q39226768-00BCA457-E817-4C94-A039-8BC65F7E726D Q42364461-BA20AD2E-C638-4C50-A8A3-F84F0494FC25 Q42379773-ABFC8234-528E-48AB-835A-46F3178EFD7A Q47125538-D01BFE65-4A3E-4AE2-A6C0-AB579C4AFE98 Q47661714-E51B661C-A766-4614-9863-940E6D0252DA Q47943733-F6F76901-56E7-43EF-9F55-83C69624E297 Q48343913-0BC714AA-72F4-4E4D-A0B7-F98678283F05 Q50181533-DC60D1FB-3825-49F1-9EEC-7E3DD6D3C0EF Q53282671-94241CB0-6E5D-43DC-A183-A574E690CFA3 Q54985799-CDC4AF22-940A-4043-B43A-C33F8C25F2A8 Q55131706-B5E7D655-B8A2-434A-9BD3-28EDF85C556D Q55434066-C50C19DA-24EE-486E-B1EA-50F08BF654A2 Q55512190-B3B2DA01-BDC8-4EC5-B9BE-90409FD0E00F Q55981706-116DC0CE-B5CB-47D6-A32D-F36AAC0E1BAA Q57388869-F2C3B3AE-7C3F-4D29-9EAC-0FAA96A0A888 Q58553344-7E693FD2-4138-48CB-85E1-9446F3F477B2 Q58696861-8094C425-1185-4073-83F7-806658C1F89C Q58763035-42F42C22-0097-439E-9FF2-6B6D4806EF3B Q58784324-D67856CA-C00C-4CEA-BBE4-0901277D28C7 Q58803252-1958554D-0AB8-4593-B8CC-714881681BA9 Q59126241-34BABFDA-6E5C-439A-A3DD-96350055A539

P2860

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

http://www.wikidata.org/entity/Q47607188

description

2016 nî lūn-bûn

@nan

2016年の論文

@ja

2016年学术文章

@wuu

2016年学术文章

@zh-cn

2016年学术文章

@zh-hans

2016年学术文章

@zh-my

2016年学术文章

@zh-sg

2016年學術文章

@yue

2016年學術文章

@zh

2016年學術文章

@zh-hant

name

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@en

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@nl

type

label

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@en

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@nl

prefLabel

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@en

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice.

@nl

P1433

Q47607188-BDC3723C-D735-499E-90C7-492950411A78

P1476

Q47607188-D03DD8F2-F565-4596-B374-B3C24A738B73

P2093

Q47607188-10395953-D29A-4686-9CCA-525CA2B09E92

Q47607188-31A35B9D-1092-45BF-9506-D38261118393

Q47607188-31B46761-04FA-4FC5-A974-852C9F1C1AEF

Q47607188-3564D1DE-C9E7-4AFF-B55F-02C34C55D6F7

Q47607188-43D1C46E-659D-4D03-ACEA-4B5CA3DB4EBE

Q47607188-5158B98F-6A9B-4076-A041-55BF6F0461F1

Q47607188-63179EB7-F5FC-4539-B324-CDC6787099F6

Q47607188-A5B271AC-5F1A-4F39-8294-9AC59B490936

Q47607188-A78BD2F5-A993-4F9A-957B-411E4D1A9D02

P304

Q47607188-EB5E36DB-9513-478E-AA2D-05DED217C0E1

P31

Q47607188-46D54EBB-ED67-4F64-A16E-DBC4D997B608

P356

Q47607188-12C0DF19-3C3A-4517-9634-3B6A18AB713A

P407

Q47607188-B4CFDD4E-02F5-44DF-806E-336FD180F2C3

P433

Q47607188-7CC7B64F-899C-4842-95F5-41228731A313

P478

Q47607188-981E49DA-9599-4993-A6FD-AACC3A01A9FF

P50

Q47607188-02F5B244-EB65-469D-A636-7B2DACF2DEA6

Q47607188-0E04F3CB-C294-44F5-887E-E934874449B1

Q47607188-52B6FC58-A364-41A8-A0EE-64E24EC05C51

Q47607188-901B05FF-C2A9-4A00-999F-AE92B2FD1B19

P577

Q47607188-7AB0EC54-0B39-49E3-AFE8-DDF5A1360856

P698

Q47607188-535DF1FD-C0B3-4B33-B2F7-23B381F66740

P356

P1433

The New England Journal of Medicine

P1476

Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice

@en

P2093

Catherine Harvey

http://www.w3.org/2001/XMLSchema#string

David Leather

http://www.w3.org/2001/XMLSchema#string

Henrik Svedsater

http://www.w3.org/2001/XMLSchema#string

Jodie Crawford

http://www.w3.org/2001/XMLSchema#string

Lucy Frith

http://www.w3.org/2001/XMLSchema#string

Nawar Diar Bakerly

http://www.w3.org/2001/XMLSchema#string

Salford Lung Study Investigators

http://www.w3.org/2001/XMLSchema#string

Sheila McCorkindale

http://www.w3.org/2001/XMLSchema#string

Susan Collier

http://www.w3.org/2001/XMLSchema#string

P304

1253-1260

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1056/NEJMOA1608033

http://www.w3.org/2001/XMLSchema#string

P407

P433

13

http://www.w3.org/2001/XMLSchema#string

P478

375

http://www.w3.org/2001/XMLSchema#string

P50

Ashley Woodcock

P577

2016-09-04T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27593504

http://www.w3.org/2001/XMLSchema#string